| Previous close | 1.9000 |
| Open | N/A |
| Bid | 0.0000 |
| Ask | 1.4500 |
| Strike | 15.00 |
| Expiry date | 2024-06-21 |
| Day's range | 1.9000 - 1.9000 |
| Contract range | N/A |
| Volume | |
| Open interest | 5 |
Business WireEnanta Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference
WATERTOWN, Mass., May 29, 2024--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2024 at 7:30 a.m. ET in New York, NY.
Simply Wall St.Enanta Pharmaceuticals Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Enanta Pharmaceuticals ( NASDAQ:ENTA ) Second Quarter 2024 Results Key Financial Results Revenue: US$17.1m (down 4.2...
Insider MonkeyEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q2 2024 Earnings Call Transcript
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q2 2024 Earnings Call Transcript May 6, 2024 Enanta Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon and welcome to Enanta Pharmaceuticals’ Fiscal Second Quarter Financial Results Conference Call. At this time, […]
